SCHEMBL14396846

SCHEMBL14396846

c1cc(Oc2ccc3nc(NC4CCCCC4)sc3c2)cc(-c2cnn(CCN3CCCC3)c2)n1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 16/20 0.49
▸ PDGFRB P09619 4/20 0.46
▸ PDGFRA P16234 4/20 0.46
▸ FLT3 P36888 4/20 0.46
▸ KIT P10721 2/20 0.46
▸ TTK P33981 1/20 0.40
▸ KDR P35968 2/20 0.40
▸ MET P08581 1/20 0.40
▸ FGFR1 P11362 1/20 0.40
▸ FGFR2 P21802 1/20 0.40
▸ FGFR4 P22455 1/20 0.40
▸ FGFR3 P22607 1/20 0.40
▸ NPC1 O15118 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ PKM P14618 1/20 0.38
▸ RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14396851 0.95 CSF1R (0.47) CSF1RPDGFRBPDGFRAFLT3KIT
SCHEMBL14396651 0.95 CSF1R (0.47) CSF1RPDGFRBPDGFRAFLT3KIT
SCHEMBL14396857 0.95 CSF1R (0.47) CSF1RPDGFRBPDGFRAFLT3KIT
SCHEMBL14396824 0.91 CSF1R (0.51) CSF1RPDGFRBPDGFRAFLT3KIT
SCHEMBL14396483 0.91 CSF1R (0.51) CSF1RPDGFRBPDGFRAFLT3KIT
SCHEMBL2676799 0.89 CSF1R (0.55) CSF1RPDGFRBPDGFRAFLT3KIT
SCHEMBL14396853 0.89 CSF1R (0.44) CSF1RPDGFRBPDGFRAFLT3KIT
SCHEMBL14396855 0.89 CSF1R (0.49) CSF1RPDGFRBPDGFRAFLT3KIT
SCHEMBL14396825 0.89 CSF1R (0.49) CSF1RPDGFRBPDGFRAFLT3KIT
SCHEMBL14397057 0.89 CSF1R (0.52) CSF1RPDGFRBPDGFRAFLT3KIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007121484-A2 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING NOVARTIS AG (CH) 2007-10-25 — — WO disclosed
Send feedback